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In 1962 Rolf Luft became the first clinician to recognize mitochondrial dysfunction as a cause of disease. Nearly 
50 years later, the field of mitochondrial toxicology is getting a fresh boost with the realization that environmental 
agents may play a significant role in many mitochondrial diseases. 
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ook into any cell today, and you’ll see remnants of ancient bacteria by the thou-
sands. These mitochondria—tiny organelles in the cell that each possess their own 
DNA—have come under a growing scientific spotlight; scientists increasingly 
believe they play a central role in many, if not most, human illnesses. Exquisitely sensitive to 
environmental threats, mitochondria convert dietary sugars into a high-energy molecule—
adenosine triphosphate (ATP)—that cells use as fuel. And when mitochondria falter, cells 
lose power, just as a flashlight dims when its batteries weaken. Now scientists are linking 
environmental interactions with the mitochondria to an array of metabolic and age-related 
maladies, including cancer, autism, type 2 diabetes, Alzheimer disease, Parkinson disease, 
and cardiovascular illness. 
Surge in Awareness
Mitochondrial disease was featured as a research theme during the Society of Toxicology’s 
(SOT) 2010 annual meeting. Michael Holsapple, who chaired SOT’s science program 
committee, attributes that decision to a growing realization among toxicologists that mito-
chondrial genomes are uniquely susceptible to oxidative damage and stress. “They’ve got a 
much higher percentage of coding DNA in contrast to nuclear genomes, which contain long 
noncoding regions,” explains Holsapple, who is executive director of the International Life 
Sciences Institute’s Health and Environmental Sciences Institute in Washington, DC. “And 
what we’re learning is that they play a significant role in neurodegenerative diseases and 
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metabolic syndrome, which is a more amor-
phous designation that reflects an epidemic 
of obesity. We see this as cutting-edge 
science.” 
Growing awareness of the role of mito-
chondria in health has sparked a surge in the 
number of scientists who study the topic. 
“A few years ago, there were just a handful 
of us,” says Kendall Wallace, a toxicologist 
and professor at the University of Minnesota 
Medical School. “Now we’ve got a critical 
mass of scientists with active research pro-
grams generating data.” But understanding 
the role of mitochondria in health and dis-
ease doesn’t come easily. 
Each cell contains hundreds or even thou-
sands of mitochondria. And cells falter only 
when their mitochondrial content (or “copy 
number”) drops below a critical threshold. 
Douglas Wallace, a professor at the Univer-
sity of California, Irvine, says mitochondrial 
research aims for a union between two fun-
damental components in biology: structural 
components (such as genes, proteins, tissues, 
and organs) and bioenergetic components 
(which relate to energy metabolism and how 
it sustains living systems). Mitochondria repre-
sent an interface between structure and energy, 
yet scientists have struggled with how to assess 
mitochondrial status, particularly in vivo.
These technical challenges compli-
cate basic research and impede efforts to 
diagnose and treat mitochondrial prob-
lems. At an NIEHS-sponsored meeting 
held 25 June 2009, participants cited an 
urgent need for assays and biomarkers that 
detect early mitochondrial damage.
1 Such 
tools might promote interventions during 
subclinical disease stages, the participants say. 
Bruce Cohen, a professor and neurologist at 
the Cleveland Clinic’s Neurological Institute 
and Taussig Cancer Center, says only a few 
hospitals have the expertise needed to diag-
nose mitochondrial conditions. Mitochon-
drial tests are expensive, he says, and they 
also lack what most doctors would consider 
to be adequate sensitivity (diagnosis of true 
cases) and specificity (accuracy in diagnosis). 
Douglas Wallace adds that because clini-
cians don’t yet have tools for measuring energy 
flows in living organisms, many mitochon-
drial conditions go undiagnosed. “Research 
groups in the mitochondrial field are scram-
bling to get tools for measuring energy deficits, 
but they’re not available to doctors who see 
patients,” he says. “So from [the perspective 
of] the practice of medicine, if you don’t have 
the test, the problem seems to not exist. But 
it’s not true that what you don’t know won’t 
hurt you—these are real phenomena, and they 
cause real health problems.” Still, the field is 
making progress, and advances in mitochon-
drial research are generating insights into how 
the environment affects mitochondrial health 
and what we can do about it, Wallace says. 
An Expanding View of 
Mitochondrial Toxicology
Mitochondria can be thought of as processing 
centers on a path that begins with sunlight 
and ends with ATP. All the energy on Earth 
can be traced back to the sun and the way 
photosynthetic life forms absorb solar rays to 
power the production of glucose from water 
and carbon dioxide. The most fundamental 
fuel on the planet, glucose is a six-carbon 
sugar. Cells break it down further in the cyto-
sol (their liquid interior) to produce smaller 
molecules, including, among others, a three-
carbon acid called pyruvate and nicotin  amide 
adenine dinucleotide (NADH). 
During ATP production, pyruvate and 
NADH are drawn into the mitochondria, 
where they undergo a complex series of 
electro  chemical reactions known collectively 
as oxidative phosphorylation.These aerobic 
reactions occur inside the mitochondria along 
what’s known as the electron transport chain 
(ETC). During oxidative phosphorylation, 
NADH transfers electrons to oxygen, and 
the energy released by that reaction is used to 
create ATP from a molecular precursor called 
adenosine diphosphate (ADP). Released into 
the cell, ATP is inherently unstable—enzymes 
break it apart to release energy for most bio-
chemical reactions. And that regenerates 
ADP, which then returns to the mitochon-
dria. According to NIEHS principal investi-
gator William Copeland, humans typically 
create and consume their own weight in ATP 
every day. 
Mitochondria  also  have  their  own 
genomes, relics of their ancient bacterial 
past. Sequenced by scientists in 1981, the 
human mitochondrial genome has more 
than 16,000 DNA base pairs (compared with 
3 billion in the human nuclear genome) that 
code for 24 RNA molecules and 13 proteins.
2 
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bout two billion years ago, primitive seas 
swarmed with a simple life form on the 
verge of a change. Amounting to little more 
than some DNA wrapped in a membrane, this 
“proto-eukaryote” powered itself with a type 
of metabolism called glycolysis. Proto-
eukaryotes were relics of an earlier time, 
when volcanic gases dominated the 
atmosphere. Now photosynthetic algae were 
on the scene, and they were filling the 
atmosphere with oxygen. The appearance of 
oxygen was transforming. Bacteria started 
burning it with a new, more efficient kind of 
metabolism—aerobic respiration—which 
gave them a competitive advantage. But not 
to be outdone, proto-eukaryotes simply 
engulfed the bacteria, to their mutual 
advantage: bacteria supplied their hosts with 
energy, and in exchange, the proto-eukaryote 
supplied nutrients and protection. And over 
the next 1.2 billion years, they co-evolved 
into eukaryotic cells—the basic units of plant 
and animal life.Focus | Mito-Conundrum
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The nuclear genome also codes for roughly 
1,500 mitochondrial proteins.
Beyond making ATP, mitochondria have 
other important functions. For instance, they 
generate reactive oxygen species (ROS), or 
free radicals, which participate in cell signal-
ing and communication, particularly between 
nuclear and mitochondrial genes. Excessive 
ROS also can be toxic, and elevated levels 
can trigger a type of programmed cell death 
called apoptosis. Scientists have, in fact, linked 
asbestos-induced elevations in ROS to apop-
tosis in alveolar epithelial cells,
3 which could 
explain how asbestos causes lung disease. 
In yet another crucial function, mitochon-
dria regulate intracellular stores of calcium, but 
sometimes that leads to too much of a good 
thing. When the mitochondria absorb excess 
calcium, they initiate apoptosis, and evidence 
suggests this activity in nerve cells might con-
tribute to Alzheimer disease.
4
Mitochondrial diseases generally have 
been thought of as a spectrum of primar-
ily inherited conditions afflicting roughly 1 in 
every 2,000–5,000 people, says Cohen; about 
1 in 200 people in the general population 
are thought to carry potentially pathogen-
ic mitochondrial DNA mutations.
5 Many 
mitochondrial conditions share common but 
nonspecific symptoms, such as fatigue and 
muscle pain. Others have more precise and 
debilitating features. For instance, MELAS 
(short for mitochondrial encephalomyopathy, 
lactic acidosis, and strokelike episodes), which 
is caused by inherited mutations in mitochon-
drial DNA, leads to seizures, migraines, and 
brain damage. Almost invariably fatal, the 
illness emerges when physical exertion over-
whelms the body’s energy-generating capacity. 
Beyond genetic causes, scientists now 
attach growing importance to environmental 
factors that trigger mitochondrial problems. In 
some cases, illness ensues only when chemical 
exposures interact with genetic risk factors. 
In one classic gene–environment interaction, 
people with an inherited mutation at allele 
1555 of mitochondrial DNA (found in 1 of 
every 1,200 people) will have a high likelihood 
of deafness with exposure to aminoglycoside 
antibiotics such as gentamicin, says Cohen. 
Other genetic factors modify the severity of 
this effect. Cohen says a simple genetic test for 
the mutation is available and could be consid-
ered reasonable to add to newborn screening 
for metabolic disorders, so as to avoid amino-
glyosides if at all possible in those carrying 
this mutation. Likewise, a number of mito-
chondrial DNA mutations predispose people 
to Leber hereditary optic neuropathy, a severe 
visual loss that usually occurs in young adults. 
Visual loss may be more frequent and severe 
in people who drink alcohol or smoke ciga-
rettes; those who quit experience some return 
of visual function, Cohen adds. This condition 
also can be diagnosed with a genetic test. 
The Field Emerges
According to Dean Jones, a professor at 
Emory University School of Medicine, mod-
ern mitochondrial research dates back to the 
1940s. That’s when scientists realized that 
when cyanide and carbon monoxide bind 
with hemoglobin in red blood cells, they take 
oxygen out of circulation, blocking energy 
production in the mitochondria. Over time, 
other aspects of mitochondrial function were 
revealed. Oxidative phosphorylation was 
described in more detail in the 1960s and 
calcium regulation in the 1970s, and by the 
1990s, researchers had discovered that mito-
chondria coordinate apoptosis, which was a 
groundbreaking finding. Until then, it was 
assumed that cell death from mitochondrial 
dysfunction resulted mainly from failures in 
ATP production. 
When scientists found that mitochondria 
release several proteins (including cytochrome 
C and apoptosis-inducing factor) to actively 
trigger cell death,
6 the field was turned on its 
head. “That finding brought in a brand new 
audience of investigators,” Kendall Wallace 
says. “Suddenly, we had researchers involved 
in cell cycling, signaling, and cancer all work-
ing on the mitochondria; it really added to a 
growth of interest in the field.”
Another crucial development came when 
scientists detected organ toxicity in HIV/AIDS 
patients treated with azidothyramidine (AZT). 
This drug, commercialized during the late 
1980s, transformed HIV/AIDS from a certain 
death sentence to a manageable chronic condi-
tion. But within a few years, as many as 30% 
of patients treated with AZT (and other drugs 
in its class) were developing complications 
such as weakening heart muscles and vision 
loss. Researchers soon implicated mitochon-
drial toxicity in these effects.
7 AZT is designed 
to inhibit an enzyme, DNA polymerase, which 
is involved in HIV replication. But mitochon-
drial DNA polymerase gamma (pol γ) also is 
targeted, resulting in abnormal mitochondrial 
and cell function. As mitochondrial perfor-
mance drops, cells revert back to glycolysis—a 
more primitive, less efficient mechanism—to 
generate ATP. That change in metabolism 
is reflected by a build-up of lactic acid, a by-
product of glycolysis, which can be used as a 
biomarker of mitochondrial failure.
7 In fact, 
recent evidence shows a link between autism 
and a build-up of lactic acid in serum, suggest-
ing a possible role for mitochondrial dysfunc-
tion in the etiology of this disease.
8
According to Yvonne Will, an associate 
research fellow at Pfizer Global Research and 
Development, the link between AZT and 
mitochondrial side effects raised the awareness 
that drugs could have mitochondrial liabilities. 
She says it was soon found that members of 
other drug families including the antilipidemic, 
antidiabetic, antidepressant, beta-blocker, and 
nonsteroidal anti-inflammatory drug classes 
also showed potential to induce mitochon-
drial side effects. This led to the development 
of high-throughput screens for mitochon-
drial damage that are now routinely deployed 
throughout the drug discovery process.
Environmental Toxicology 
Takes Note
Compared with pharmaceutical research, 
environmental toxicology is only now get-
ting up to speed on the effects of chemicals 
on mitochondrial functioning. Copeland 
says mitochondria are like canaries in a 
coalmine: susceptible to early-stage effects 
that predict cell and organ toxicity later. 
Research shows that mitochondrial DNA is 
Mitochondrial diseases generally have been thought of as a spectrum 
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Mitochondrial Diseases
Alpers Disease
Barth Syndrome
Beta-Oxidation Defects
Carnitine Deficiency
Carnitine-Acyl-Carnitine Deficiency
Carnitine Palmitoyl Transferase (CPT) I Deficiency
Carnitine Palmitoyl Transferase (CPT) II Deficiency
Chronic Progressive External Ophthalmoplegia 
Syndrome
Coenzyme Q10 Deficiency
Complex I Deficiency
Complex II Deficiency
Complex III Deficiency
Complex IV Deficiency
Complex V Deficiency
Cytochrome C Oxidase (COX) Deficiency
Creatine Deficiency Syndromes
Kearns-Sayre Syndrome
Lactic Acidosis
Leber Hereditary Optic Neuropathy
Leigh Disease
Lethal Infantile Cardiomyopathy
Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency
Long-Chain Acyl-CoA Dehydrogenase Deficiency
Luft Disease
Medium-Chain Acyl-CoA Dehydrogenase Deficiency
Mitochondrial DNA Depletion
Mitochondrial Encephalopathy
Mitochondrial Encephalomyopathy, Lactic Acidosis, and 
Strokelike Episodes
Mitochondrial Myopathy
Mitochondrial Recessive Ataxia Syndrome
Multiple Acyl-CoA Dehydrogenase Deficiency/Glutaric Aciduria 
Type II
Myoclonic Epilepsy and Ragged-Red Fiber Disease
Myoneurogastrointestinal Disorder and Encephalopathy
Neuropathy, Ataxia, and Retinitis Pigmentosa
Pearson Syndrome
Pyruvate Carboxylase Deficiency
Pyruvate Dehydrogenase Deficiency
Short-Chain Acyl-CoA Dehydrogenase Deficiency
Short-Chain-3-hydroxyacyl-CoA Dehydrogenase Deficiency
Very Long-Chain Acyl-CoA Dehydrongenase Deficiency
Source: United Mitochondrial Disease Foundation
T
he distinctive folds of the inner membrane of each 
mitochondrion are known as cristae. The looping cristae 
offer maximum surface area for the important work of 
converting oxygen and sugars into energy via a series of 
reactions, with the electron transport chain producing the 
final energy payout. In a normal mitochondrion, the cristae 
fill the interior, but damaged or dysfunctional mitochondria 
lose cristae. 
If there is an error in any of the myriad steps involved in 
energy production, organ and system function can falter. 
Dozens of rare diseases have been shown to result from 
mitochondrial dysfunction (see list above). Several others—
including Alzheimer disease, autism, cancer, cardiovascular 
disease, Parkinson disease, and type 2 diabetes—are 
suspected to involve the mitochondria.Focus | Mito-Conundrum
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uniquely susceptible to the damaging effects 
of ROS.
9 These effects are more extensive 
and longer-lasting in mitochondrial DNA 
than they are in the nuclear genome, he 
adds, which suggests that relatively minor 
additional stress—alcohol, cigarette smoke, 
or other toxicants, for instance—could tip 
someone toward metabolic illness.
Joel Meyer, an assistant professor at 
Duke University, adds that, compared with 
its nuclear counterpart, mitochondrial DNA 
generally has less capacity to repair itself. It 
specifically can’t delete the large DNA helix–
distorting adducts formed when mitochon-
drial DNA bases are damaged by mutagens 
such as polyaromatic hydrocarbons and ultra-
violet radiation. The toxicologic implications 
of these adducts are now under investiga-
tion. “Our hypothesis is that [adducts lead] to 
altered transcription of mitochondrial genes, 
changes in mitochondrial copy number, mito-
chondrial mutations, and compromised ETC 
functioning,” Meyer says.
Another factor exacerbates the sensitivity 
of mitochondrial genetics, Copeland adds, that 
being reliance on just one enzyme—pol γ—for 
both replication and repair of mitochondrial 
DNA. In contrast, the nuclear genome has 
15 such enzymes, he says. According to Cope-
land’s research, more than 85% of spontaneous 
mitochondrial DNA mutations can be traced 
back to errors in the POLG gene that encodes 
pol γ.
10 Those mutations accumulate over time, 
so that with age individuals become less able to 
recover from environmental exposures. 
This diminished capacity likely plays an 
important role in age-related illnesses, Cope-
land says. “It’s well known that mitochondrial 
DNA mutations and deletions accumulate 
during aging,” he explains. “Mouse models 
show that if you accelerate mitochondrial 
degeneration, you get premature aging. We 
already know that older people can’t run mar-
athons as well as younger people and are more 
susceptible to environmental toxicants, possi-
bly due to the accumulation of more damaged 
mitochondria.” 
Copeland’s research has helped to iden-
tify approximately 200 POLG mutations 
in disease. Among them, more than 80 are 
linked to a neurologic and hepatic condition 
known as Alper disease, which typically afflicts 
young children, who rarely live past 10 years. 
A later-onset form of Alper disease can be 
triggered by environmental factors, Copeland 
says, particularly viruses. “But avoiding viruses 
is admittedly hard to do,” he adds. 
Other  environmental  chemicals  are 
thought to interact directly with the ETC, 
which has five distinct complexes (or trans-
membrane protein structures), each with its 
own task in energy production. Scientists Tim 
Greenamyre of the University of Pittsburgh 
and Todd Sherer of the Michael J. Fox Foun-
dation for Parkinson’s Research have shown 
that several pesticides, including rotenone 
and pyridaben, alter complex I, and that the 
resulting oxidative stress damages cells.
11 In 
fact, rotenone exposure is an experimental 
model for Parkinson disease in animals, which 
develop analogous symptoms following intra-
venous and subcutaneous administration of the 
chemical, as shown in unpublished research by 
Meyer. Several epidemiologic studies suggest 
an association between Parkinson disease and 
pesticide exposure,
12 but scientists have yet to 
pinpoint a specific pesticide in disease onset.
The reality is that from an environmental 
perspective, these are still early days for mito-
chondrial toxicity research, says Meyer. In his 
opinion, although mitochondrial toxicants have 
been identified, the field still lacks a “slam-
dunk” association between ambient chemi-
cal exposures and chronic toxicity and disease 
resulting from mitochondrial disruption, such 
as the one that exists for AZT and its side effects 
in HIV/AIDS patients. “That [discovery] was a 
defining event for the pharmaceutical industry, 
but we don’t have an equivalent for that in 
environmental health,” he says. 
According to Kendall Wallace, excep-
tions could be the pesticides rotenone and 
cyanide, which inhibit ETC and deprive cells 
of ATP, and pentachlorophenol, which has 
been implicated in the weight loss associated 
with its use as an antifungal agent in wood 
treatments. “Broadening the definition of 
mitochondrial toxicity to include mitochon-
drial targets beyond the ETC brings many 
additional environmental agents into the 
fold,” he says. “Examples include fluoro-
acetate and fluoroacetamide, which inhibit 
the tricarboxylic acid cycle, and alkyl acids 
that inhibit the transport and/or oxidation 
of fats. Both of these metabolic pathways are 
localized within the matrix of the mitochon-
dria, and both toxicities are manifested as a 
metabolic or bioenergetic disease.”
One thing that’s needed, Meyer says, are 
better ways to evaluate mitochondrial func-
tion in whole organisms. Chemical effects 
on isolated mitochondria can be detected 
using polymerase chain reaction methods that 
measure DNA damage, or with oxygen sen-
sors that measure aerobic respiration. “But by 
comparison, measurements in vivo are more 
challenging because mitochondrial biology 
varies with tissues and developmental stage, 
Meyers says.
13 
Energy Sense
According to Jones, growing acknowledge-
ment of the role of mitochondria in dis-
ease makes intuitive sense. “Everything in 
our body is dependent on energy metabo-
lism,” he says. “So if something alters that 
metabolism or the cell-death signaling path-
ways, you would expect this is going to 
have impacts on the full range of diseases. 
Just the fundamental act of being alive, our 
activity levels, behaviors, diet, and infec-
tion—everything factors in to this. The 
challenge for us is to identify the environ-
mental risks that we can actually do some-
thing about.”
Until we gain a clearer understanding of 
which specific environmental agents damage 
mitochondria and how they do it, Cohen 
says it is probably safe to assume that eating 
a sensible, nutritious diet is one of the best 
protections against mitochondrial damage. 
“Overeating creates an increase in free radical 
formation and generates internal toxins,” he 
says. “My guess is that for the average person 
not living near a toxic waste dump there are 
more internal poisons from overeating than 
the person will be exposed to in everyday 
life. As my grandmother always said, eat your 
vegetables and get exercise.”
Charles W. Schmidt, MS, an award-winning science writer 
from Portland, ME, has written for Discover Magazine, 
Science, and Nature Medicine. 
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